HLA-DR Antibody (37.68)
Novus Biologicals, part of Bio-Techne | Catalog # NB100-65424
Conjugate
Catalog #
Key Product Details
Species Reactivity
Sheep
Applications
Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunoprecipitation
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2A Clone # 37.68
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Splenocytes from ATL mice
Reactivity Notes
Predicted cross-reactivities: Bovine, Goat, Human
Specificity
NB100-65424 recognizes a monomorphic epitope on ovine MHC class II DR molecules. The distribution of ovine DR molecules on T lymphocytes has been shown to vary with immune status and age. Initially T lymphocytes lack class II molecules, then T lymphocytes progressively express DR molecules.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for HLA-DR Antibody (37.68)
Application
Recommended Usage
Flow Cytometry
1:50-1:200
Immunohistochemistry
1:10-1:500
Immunohistochemistry-Frozen
1:10-1:500
Immunoprecipitation
1:10-1:500
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: HLA-DR
Given the role in adaptive immunity, HLA-DR allele polymorphisms, gene misexpression, and dysfunction has been implicated in many diseases ranging from autoimmune disorders to cancer (2). HLA-DR is also a classical biomarker for disease, including sepsis where reduced expression of HLA-DR molecules on monocytes, as measured by flow cytometry, indicates diagnosis and prognosis (4,5). Immunosuppression observed with sepsis results in decreased surface expression of HLA-DR and concurrent increase in expression of programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and B and T lymphocyte attenuator (BTLA) (4). This altered expression results in poor T cell response and apoptosis, along with reduced interferon-gamma (IFN-gamma) production and increased pro-inflammatory cytokine release (4). Furthermore, the decrease in HLA-DR expression is also correlated with the decrease in CD14lowCD16+ inflammatory monocytes (5). Interestingly, COVID-19 patients also exhibit a reduction in HLA-DR that correlates with disease severity and immunosuppression (5).
References
1. Andersson G. (1998). Evolution of the human HLA-DR region. Frontiers in bioscience : a journal and virtual library. https://doi.org/10.2741/a317
2. Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009). The HLA genomic loci map: expression, interaction, diversity and disease. Journal of human genetics. https://doi.org/10.1038/jhg.2008.5
3. Stern, L. J., & Calvo-Calle, J. M. (2009). HLA-DR: molecular insights and vaccine design. Current pharmaceutical design. https://doi.org/10.2174/138161209789105171
4. Zhuang, Y., Peng, H., Chen, Y., Zhou, S., & Chen, Y. (2017). Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis. Frontiers in bioscience (Landmark edition). https://doi.org/10.2741/4547
5. Benlyamani, I., Venet, F., Coudereau, R., Gossez, M., & Monneret, G. (2020). Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review. Cytometry. Part A : the journal of the International Society for Analytical Cytology. https://doi.org/10.1002/cyto.a.24249
Long Name
Major Histocompatibility Complex Class II DR
Alternate Names
HLA-DRA, HLADR, MHC Class II DR
Gene Symbol
HLA-DRA
Additional HLA-DR Products
Product Documents for HLA-DR Antibody (37.68)
Product Specific Notices for HLA-DR Antibody (37.68)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...